vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $281.3M, roughly 1.2× Guardant Health, Inc.). Walker & Dunlop, Inc. runs the higher net margin — -12.9% vs -45.7%, a 32.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -0.4%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-680.1M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 22.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
GH vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $340.0M |
| Net Profit | $-128.5M | $-13.9M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | -17.2% |
| Net Margin | -45.7% | -12.9% |
| Revenue YoY | 39.4% | -0.4% |
| Net Profit YoY | -15.8% | -131.0% |
| EPS (diluted) | $-1.01 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $340.0M | ||
| Q3 25 | $265.2M | $337.7M | ||
| Q2 25 | $232.1M | $319.2M | ||
| Q1 25 | $203.5M | $237.4M | ||
| Q4 24 | $201.8M | $341.5M | ||
| Q3 24 | $191.5M | $292.3M | ||
| Q2 24 | $177.2M | $270.7M | ||
| Q1 24 | $168.5M | $228.1M |
| Q4 25 | $-128.5M | $-13.9M | ||
| Q3 25 | $-92.7M | $33.5M | ||
| Q2 25 | $-99.9M | $34.0M | ||
| Q1 25 | $-95.2M | $2.8M | ||
| Q4 24 | $-111.0M | $44.8M | ||
| Q3 24 | $-107.8M | $28.8M | ||
| Q2 24 | $-102.6M | $22.7M | ||
| Q1 24 | $-115.0M | $11.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | -17.2% | ||
| Q3 25 | -37.3% | 13.6% | ||
| Q2 25 | -45.9% | 14.5% | ||
| Q1 25 | -54.6% | 2.2% | ||
| Q4 24 | -62.4% | 15.3% | ||
| Q3 24 | -61.3% | 12.8% | ||
| Q2 24 | -56.8% | 10.4% | ||
| Q1 24 | -59.2% | 6.0% |
| Q4 25 | -45.7% | -12.9% | ||
| Q3 25 | -35.0% | 9.9% | ||
| Q2 25 | -43.0% | 10.6% | ||
| Q1 25 | -46.8% | 1.2% | ||
| Q4 24 | -55.0% | 13.1% | ||
| Q3 24 | -56.3% | 9.9% | ||
| Q2 24 | -57.9% | 8.4% | ||
| Q1 24 | -68.2% | 5.2% |
| Q4 25 | $-1.01 | $-0.41 | ||
| Q3 25 | $-0.74 | $0.98 | ||
| Q2 25 | $-0.80 | $0.99 | ||
| Q1 25 | $-0.77 | $0.08 | ||
| Q4 24 | $-0.90 | $1.32 | ||
| Q3 24 | $-0.88 | $0.85 | ||
| Q2 24 | $-0.84 | $0.67 | ||
| Q1 24 | $-0.94 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $299.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.7B |
| Total Assets | $2.0B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $299.3M | ||
| Q3 25 | $580.0M | $274.8M | ||
| Q2 25 | $629.1M | $233.7M | ||
| Q1 25 | $698.6M | $181.0M | ||
| Q4 24 | $525.5M | $279.3M | ||
| Q3 24 | $585.0M | $179.8M | ||
| Q2 24 | $933.7M | $208.1M | ||
| Q1 24 | $1.0B | $216.5M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $1.7B | ||
| Q3 25 | $-354.5M | $1.8B | ||
| Q2 25 | $-305.5M | $1.8B | ||
| Q1 25 | $-250.8M | $1.7B | ||
| Q4 24 | $-139.6M | $1.7B | ||
| Q3 24 | $-60.1M | $1.7B | ||
| Q2 24 | $-1.6M | $1.7B | ||
| Q1 24 | $68.3M | $1.7B |
| Q4 25 | $2.0B | $5.1B | ||
| Q3 25 | $1.3B | $5.8B | ||
| Q2 25 | $1.3B | $4.7B | ||
| Q1 25 | $1.3B | $4.5B | ||
| Q4 24 | $1.5B | $4.4B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.6B | $4.2B | ||
| Q1 24 | $1.7B | $3.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-664.3M |
| Free Cash FlowOCF − Capex | $-54.2M | $-680.1M |
| FCF MarginFCF / Revenue | -19.3% | -200.0% |
| Capex IntensityCapex / Revenue | 9.9% | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-664.3M | ||
| Q3 25 | $-35.4M | $-948.1M | ||
| Q2 25 | $-60.3M | $-238.5M | ||
| Q1 25 | $-62.7M | $-281.1M | ||
| Q4 24 | $-64.5M | $129.4M | ||
| Q3 24 | $-51.1M | $-202.0M | ||
| Q2 24 | $-94.0M | $-237.8M | ||
| Q1 24 | $-30.3M | $38.4M |
| Q4 25 | $-54.2M | $-680.1M | ||
| Q3 25 | $-45.8M | $-950.4M | ||
| Q2 25 | $-65.9M | $-241.0M | ||
| Q1 25 | $-67.1M | $-284.7M | ||
| Q4 24 | $-83.4M | $116.4M | ||
| Q3 24 | $-55.3M | $-204.0M | ||
| Q2 24 | $-99.1M | $-241.7M | ||
| Q1 24 | $-37.2M | $35.2M |
| Q4 25 | -19.3% | -200.0% | ||
| Q3 25 | -17.3% | -281.5% | ||
| Q2 25 | -28.4% | -75.5% | ||
| Q1 25 | -33.0% | -120.0% | ||
| Q4 24 | -41.3% | 34.1% | ||
| Q3 24 | -28.9% | -69.8% | ||
| Q2 24 | -55.9% | -89.3% | ||
| Q1 24 | -22.1% | 15.4% |
| Q4 25 | 9.9% | 4.6% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 2.4% | 0.8% | ||
| Q1 25 | 2.2% | 1.5% | ||
| Q4 24 | 9.4% | 3.8% | ||
| Q3 24 | 2.2% | 0.7% | ||
| Q2 24 | 2.9% | 1.4% | ||
| Q1 24 | 4.1% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× | ||
| Q1 24 | — | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WD
Segment breakdown not available.
